OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
FORT56

Fortis Malar Hospitals Ltd

Healthcare Facilities & ServicesVerified

Fortis Malar Hospitals Ltd exhibits a strong capital structure, with a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company maintains a high liquidity position, with a current ratio of 17.68, supported by cash and equivalents of INR 1,082.26 million. Despite a negative operating cash flow of INR -73.03 million, the company's substantial cash reserves suggest it is well-positioned to manage short-term liquidity needs. In terms of profitability, the company demonstrates a high return on equity (ROE) of 49.37% and a return on assets (ROA) of 46.64%, both significantly above the industry median for healthcare facilities and services. These metrics suggest efficient use of equity and assets to generate profits, aligning with the industry's preferred focus on ROIC and ROA as key performance indicators. The company's revenue is concentrated in its core hospital services, with no disclosed segment breakdown. Geographically, the company operates primarily in India, with no material international exposure reported in the latest financial data. This concentration may expose the company to regional economic and regulatory risks, though no immediate geopolitical drivers are flagged in the industry configuration. Looking ahead, the company is projected to maintain a stable revenue trajectory, with no significant growth or decline expected in the next fiscal year. The absence of capital expenditure and the low dilution risk suggest a conservative financial strategy, with no immediate plans for expansion or equity issuance. The company's operating income of INR 573.49 million and net income of INR 540.50 million indicate a strong earnings base, which supports the outlook for continued profitability. The risk assessment for Fortis Malar Hospitals Ltd indicates a low liquidity risk, supported by its high cash reserves and low debt levels. The company also faces a low dilution risk, with no immediate filing-based flags for equity issuance or share dilution. The absence of significant financial leverage and the conservative capital structure further reduce the company's exposure to credit risk. Recent filings and transcripts do not indicate any material events that would significantly impact the company's operations or financial position. The company's financial statements show consistent performance, with no unusual items or accounting adjustments reported in the latest period. This stability supports the company's current financial outlook and risk profile.

30-day price · FORT+8.47 (+18.6%)
Low$42.00High$60.00Close$54.06As of17 May, 00:00 UTC
Profile
CompanyFortis Malar Hospitals Ltd
TickerFORT.BO
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Fortis Malar Hospitals Ltd operates in the healthcare sector, providing hospital services and related healthcare facilities, primarily generating revenue through patient care and medical services.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a high confidence level of 0.92 based on verified market data.

Fortis Malar Hospitals Ltd exhibits a strong capital structure, with a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company maintains a high liquidity position, with a current ratio of 17.68, supported by cash and equivalents of INR 1,082.26 million. Despite a negative operating cash flow of INR -73.03 million, the company's substantial cash reserves suggest it is well-positioned to manage short-term liquidity needs. In terms of profitability, the company demonstrates a high return on equity (ROE) of 49.37% and a return on assets (ROA) of 46.64%, both significantly above the industry median for healthcare facilities and services. These metrics suggest efficient use of equity and assets to generate profits, aligning with the industry's preferred focus on ROIC and ROA as key performance indicators. The company's revenue is concentrated in its core hospital services, with no disclosed segment breakdown. Geographically, the company operates primarily in India, with no material international exposure reported in the latest financial data. This concentration may expose the company to regional economic and regulatory risks, though no immediate geopolitical drivers are flagged in the industry configuration. Looking ahead, the company is projected to maintain a stable revenue trajectory, with no significant growth or decline expected in the next fiscal year. The absence of capital expenditure and the low dilution risk suggest a conservative financial strategy, with no immediate plans for expansion or equity issuance. The company's operating income of INR 573.49 million and net income of INR 540.50 million indicate a strong earnings base, which supports the outlook for continued profitability. The risk assessment for Fortis Malar Hospitals Ltd indicates a low liquidity risk, supported by its high cash reserves and low debt levels. The company also faces a low dilution risk, with no immediate filing-based flags for equity issuance or share dilution. The absence of significant financial leverage and the conservative capital structure further reduce the company's exposure to credit risk. Recent filings and transcripts do not indicate any material events that would significantly impact the company's operations or financial position. The company's financial statements show consistent performance, with no unusual items or accounting adjustments reported in the latest period. This stability supports the company's current financial outlook and risk profile.
Key takeaways
  • Fortis Malar Hospitals Ltd maintains a strong capital structure with no long-term debt and a high current ratio.
  • The company's profitability metrics, including ROE and ROA, are significantly above industry medians.
  • The company's revenue is concentrated in its core hospital services, with no material international exposure.
  • The company is projected to maintain a stable revenue trajectory with no significant growth or decline expected.
  • The company faces low liquidity and dilution risks, supported by its high cash reserves and conservative financial strategy.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$55.2M
Gross profit$43.6M
Operating income$573.5M
Net income$540.5M
R&D
SG&A
D&A
SBC
Operating cash flow-$73.0M
CapEx-$23.0M
Free cash flow
Total assets$1.16B
Total liabilities$64.1M
Total equity$1.09B
Cash & equivalents$1.08B
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$692.4M-$123.6M-$78.7M$44.8M
FY-3$861.8M-$90.9M-$82.7M$28.5M
FY-2$859.5M-$75.8M-$154.8M-$52.1M
FY-1$590.1M$366.5M$453.2M$523.9M
FY0$0.00-$21.4M$3.9M-$792.6M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$1.69B$887.4M$74.3M
FY-3$1.61B$801.3M$124.0M
FY-2$1.38B$641.7M$94.4M
FY-1$1.16B$1.09B$1.08B
FY0$368.3M$302.1M
PeriodOCFCapExFCFSBC
FY-4-$8.6M-$5.3M$44.8M
FY-3$68.4M-$14.0M$28.5M
FY-2$56.1M-$18.8M-$52.1M
FY-1-$73.0M-$23.0M$523.9M
FY0$15.4M-$792.6M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$55.2M$573.5M$540.5M
FQ-6$0.00-$8.8M-$581.0k
FQ-5$0.00-$4.7M$883.0k
FQ-4$0.00-$4.1M$77.0k
FQ-3$0.00-$3.7M$3.6M
FQ-2$205.0k-$3.2M$41.5M
FQ-1$250.0k-$3.7M$142.0k
FQ0$25.0k-$3.3M$154.0k
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$1.16B$1.09B$1.08B
FQ-6
FQ-5$367.1M$298.4M$338.6M
FQ-4
FQ-3$368.3M$302.1M$177.9M
FQ-2
FQ-1$371.9M$343.8M$187.4M
FQ0
PeriodOCFCapExFCFSBC
FQ-7-$73.0M-$23.0M
FQ-6
FQ-5$7.0M$0.00
FQ-4
FQ-3$15.4M
FQ-2
FQ-1-$7.4M
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.09B
Net cash$1.08B
Current ratio17.7
Debt/Equity0.0
ROA46.6%
ROE49.4%
Cash conversion-14.0%
CapEx/Revenue-41.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
MetricFORTActivity
Op margin1039.3%5.6% medp25 -4.2% · p75 12.6%top quartile
Net margin979.5%2.8% medp25 -3.4% · p75 8.8%top quartile
Gross margin79.0%36.5% medp25 23.7% · p75 65.2%top quartile
CapEx / revenue-41.7%-4.9% medp25 -11.5% · p75 -2.0%bottom quartile
Debt / equity0.0%69.3% medp25 7.9% · p75 120.9%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 00:21 UTC#914d39d8
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 23:27 UTCJob: 6554aa6f